Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

By LabMedica International staff writers
Posted on 17 Dec 2025

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. More...

Clinicians currently lack simple, early indicators to determine which patients are responding well and which may need alternative strategies. New evidence now shows that tracking immune cell levels in the blood after treatment can reliably predict survival and treatment response.

A study led by Fox Chase Cancer Center (Philadelphia, PA, USA), in collaboration with Temple Health (Philadelphia, PA, USA), focused on absolute lymphocyte count, a standard blood measurement reflecting the number of infection-fighting white blood cells circulating in the body. During CAR T-cell therapy, a patient’s T cells are collected, genetically engineered to recognize lymphoma cells, and infused back into the bloodstream. Because this treatment relies on immune activation, researchers examined whether changes in lymphocyte levels after infusion could reflect treatment effectiveness.

Investigators analyzed patients with relapsed or refractory non-Hodgkin lymphoma treated with axicabtagene ciloleucel, a commonly used CAR T-cell therapy. Absolute lymphocyte count was measured before treatment and repeatedly during the early post-treatment period to assess both baseline levels and the speed of immune recovery. This approach relies entirely on routine blood tests already available in hospital settings, requiring no specialized assays or additional clinical burden.

The analysis showed that patients with higher baseline lymphocyte counts had significantly better progression-free survival and overall survival. In addition, a faster rise in lymphocyte levels within the first 10 days after therapy was strongly associated with complete response and longer disease control. Patients whose lymphocyte levels peaked earlier also experienced more favorable outcomes, according to the findings published in the journal Blood.

Because absolute lymphocyte count is inexpensive and widely available, it could serve as a practical early marker to guide post-treatment decisions. Patients showing poor immune recovery could be identified sooner and considered for alternative therapies before relapse occurs. Researchers plan to evaluate lymphocyte trends in other CAR T-cell products and patient populations, with the goal of refining personalized treatment strategies in lymphoma care.

“If we see that a patient has low lymphocyte counts and might relapse, we can try another strategy,” said Dr. Helen Gandler, first author of the study. “Finding a kinetic marker that doesn’t take a lot of resources to check but could still make a real difference in a patient’s course of treatment is exciting.”

Related Links:
Fox Chase Cancer Center
Temple Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.